维普期刊资源整合服务平台（V6.5）

66篇 您的检索式：作者名="Tischkowitz"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Hereditary breast cancer:new genetic developments,new therapeutic avenues显示文摘	Campeau PM Foulkes WD Tischkowitz MD	2008	Hum Genet2008，124，1：	1
2	Use of immunohistochemical markers can refine prognosis in triple negative breast cancer显示文摘	Tischkowitz M Brunet JS Begin LR	2007	BMC Cancer2007，7，：	1
3	Use of immunohisto- chemical markers can refine prognosis in triple negative breast cancer显示文摘	Tischkowitz M Brunet JS B6gin LR	2007	BMC Cancer2007，7134，：	1
4	Disruption of the Fanconi anemia - BRCA pathway in cisplatin - sen- sitive ovarian tumors 显示文摘	Taniguchi T Tischkowitz M Ameziane N	2003	Nat Med2003，9，：	1
5	Opportunities and challengesof next-generation DNA sequencing for breast units 显示文摘	Pilgrim SM Pain SJ Tischkowitz MD	2014	Br J Surg2014，101，8：	1
6	Use of immunohistochemical markers can refine prognosis in triple- negative breast cancer 显示文摘	Tischkowitz M Brunet J S Begin L R	2007	BMC Cancer2007，7，1：	1
7	Fanconi anaemia显示文摘	Tischkowitz MD Hodqson SV	2003	J Med Genet2003，40，1：	1
8	The basal phenotype of BRCA1-related breast cancer:past,present and future显示文摘	Tischkowitz MD Foulkes WD	2006	Cell Cycle2006，5，9：	1
9	Use of immunohistochemical markers can refine prognosis in triple-negative breast cancer 显示文摘	Tischkowitz M Brunet JS Begin LR	2007	BMC Cancer2007，7，：	1
10	Use of immunohistochemical markers can refine prognosis in triple negative breastcancer显示文摘	Tischkowitz M Brunet JS Bégin LR	2007	BMCCancer2007，7，：	1
11	Use of immunohistochemical markes can refine prognosis in triple negative breast cancer显示文摘	Tischkowitz M Brunet JS Begin LR	2007	BMC Cancer2007，7，：	1
12	Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors显示文摘	TANIGUCHI T TISCHKOWITZ M AMEZIANE N	2003	Nat Med2003，9，5：	1
13	Use of immunohistochemical markers can refine prognosis in triple negative breast cancer显示文摘	Tischkowitz M Brunet JS Bégin LR	2007	BMC Cancer2007，7，：	1
14	Use of immuno-histo-chemical markers can refine prognosis in triple negative breast cancer显示文摘	Tischkowitz M Brunet J S Begin L R		0，，07：	1
15	Use of immunohistochemical markers can refine prognosis in triple negative breast cancer显示文摘	Tischkowitz M Brunet JS Begin LR	2007	BMC Cancer2007，7，：	1
16	Disruption of the Fanconi anemia - BRCA pathway in cisplatin - sensitive ovarian tumors显示文摘	Taniguchi T Tischkowitz M Ameziane N	2003	Nature Med2003，9，5：	1
17	Use of immunohis-tochemical markers can refine prognosis in triple negative breast caneer显示文摘	Tischkowitz M Brunet JS B6gin LR	2007	BMC Cancer2007，7，：	1
18	The basal phenotype of BRCAL-related breast cancer: past, present and future显示文摘	Marc D Tischkowitz MD William D	2006	Cell Cycle2006，5，9：	1
19	The basal phenotype of BRCAI-related breast cancer: past, present and future 显示文摘	Tischkowitz MD Foulkes WD	2006	Cell Cycle2006，5，9：	1
20	Bi - allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia显示文摘	Tischkowitz M Ameziane N Waisfisz Q	2003	Br J Haematnl2003，123，3：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示